Novonesis Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Ester Baiget

Geschäftsführender

€3.9m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	33.3%
Amtszeit als Geschäftsführer	4.8yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	3.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ester Baiget im Vergleich zu den Einnahmen von Novonesis verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	€283m
Mar 31 2024	n/a	n/a	€332m
Dec 31 2023	€4m	€1m	€406m
Sep 30 2023	n/a	n/a	€430m
Jun 30 2023	n/a	n/a	€460m
Mar 31 2023	n/a	n/a	€487m
Dec 31 2022	€3m	€1m	€494m
Sep 30 2022	n/a	n/a	€460m
Jun 30 2022	n/a	n/a	€418m
Mar 31 2022	n/a	n/a	€416m
Dec 31 2021	€3m	€1m	€423m
Sep 30 2021	n/a	n/a	€427m
Jun 30 2021	n/a	n/a	€409m
Mar 31 2021	n/a	n/a	€389m
Dec 31 2020	€3m	€927k	€380m

Vergütung im Vergleich zum Markt: EsterDie Gesamtvergütung ($USD4.11M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Austrian ($USD4.29M).

Entschädigung vs. Einkommen: EsterDie Bezüge der Mitarbeiter sind um mehr als 20 % gestiegen, während die Unternehmensgewinne im vergangenen Jahr um mehr als 20 % gesunken sind.

Geschäftsführer

Ester Baiget (53 yo)

4.8yrs

Amtszeit

€3,903,958

Vergütung

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ester Baiget	President & CEO	4.8yrs	€3.90m	keine Daten
Rainer Lehmann	Executive VP & CFO	less than a year	€858.60k	keine Daten
Anders Lund	Chief Operating Officer	less than a year	€1.03m	keine Daten
Claus Fuglsang	Chief Scientific Officer	4.2yrs	keine Daten	keine Daten
Tobias Bjorklund	Head of Investor Relations	no data	keine Daten	keine Daten
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	keine Daten	keine Daten
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.6yrs	keine Daten	keine Daten
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.8yrs	€1.02m	keine Daten
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.6yrs	keine Daten	keine Daten
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	keine Daten	keine Daten
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	keine Daten	keine Daten
Peter Rosholm	Chief Executive Officer of Albumedix	8.8yrs	keine Daten	keine Daten

3.6yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrenes Management: NZYMDas Führungsteam des Unternehmens gilt als erfahren (3.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jesper Brandgaard	Vice Chair of the Board	less than a year	keine Daten	keine Daten
Cornelis de Jong	Independent Chairman	4.8yrs	€239.07k	0.0011% € 262.4k
Kim Stratton	Independent Director	7.8yrs	€173.33k	keine Daten
Kasim Kutay	Director	7.8yrs	€107.73k	0.00023% € 55.9k
Heine Dalsgaard	Director	4.8yrs	€143.55k	0.00065% € 157.9k
Lise Kaae	Director	less than a year	keine Daten	keine Daten
Lena Holskov	Employee Representative Director	11.8yrs	€66.91k	keine Daten
Anders Knudsen	Employee Representative Director	11.8yrs	€71.77k	keine Daten
Sharon James	Independent Director	4.8yrs	€143.55k	keine Daten
Preben Nielsen	Employee Representative Director	3.7yrs	€107.73k	0.000090% € 21.9k
Jens Obro	Employee Representative Director	3.7yrs	€71.77k	0.00012% € 29.2k
Morten Otto Sommer	Independent Director	2.7yrs	€137.51k	0.00022% € 53.5k

4.8yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrener Vorstand: NZYMDie Vorstandsmitglieder gelten als erfahren (4.8 Jahre durchschnittliche Amtszeit).

Novonesis Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Novonesis A/S Announces Board Changes

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings released

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

New minor risk - Share price stability

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: kr.2.19 (vs kr.2.92 in 2Q 2022)

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.7% yield

Independent Chairman recently bought €135k worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

New 90-day high: €51.50

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million